- Hepatitis B, C, and D Virus Infections and AFP Tumor Marker Prevalence Among the Elderly Population in Mongolia: A Nationwide Survey
-
Dambadarjaa D, Mukhtar Y, Tsogzolbaatar EO, Khuyag SO, Dayan A, Oyunbileg NE, Shagdarsuren OE, Nyam G, Yosikazu N, Takahashi M, Okamoto H
- KMID: 2530239
- J Prev Med Public Health.
- 2022 May;55(3):263-272.
- doi: 10.3961/jpmph.21.573
Objectives: Infections with hepatitis B, C, and D virus (HBV, HCV, and HDV) are a major public health problem and lead to serious complications such as cirrhosis and hepatocellular carcinoma.... -
- CITED
-
- Close
- SHARE
-
- Close
- Association between elcatonin use and cancer risk in Japan: A followup study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis
-
Okamoto H, Shibazaki N, Yoshimura T, Uzawa T, Sugimoto T
- KMID: 2503796
- Osteoporos Sarcopenia.
- 2020 Mar;6(1):15-19.
- doi: 10.1016/j.afos.2020.02.001
Objectives: On July 20, 2012, the European Medicines Agency (EMA) provided a recommendation that limits the long-term use of calcitonin. Based on this recommendation, we investigate the presence or absence... -
- CITED
-
- Close
- SHARE
-
- Close
- Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
-
Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T
- KMID: 2512105
- Intest Res.
- 2021 Jan;19(1):95-105.
- doi: 10.5217/ir.2019.09167
Background/Aims: Vedolizumab is indicated for moderately-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD). Because multiple factors may result in different pharmacokinetics and clinical efficacies, understanding determinants of vedolizumab clearance... -
- CITED
-
- Close
- SHARE
-
- Close
